XNCR (XNCR) Stock Analysis
Verdict: HOLD
A $599.8M liquid current asset buffer gives XNCR 3+ years of clinical runway, but a -155.6% net margin requires Phase 2 oncology catalyst validation.
Investment score: 53/100
Xencor presents a strong liquidity backstop with $599.8M in current assets against -$138.3M FCF burn, but clinical binary risk and negative profitability (-155.6% net margin) warrant a neutral Hold rating at $24.57.
Peers
| Peer | P/E | P/B | P/S | EV/EBITDA | ROIC % | Net margin % |
|---|---|---|---|---|---|---|
| KLRA | -7.34 | 1.18 | 0.00 | -7.94 | — | 0.00 |
| ANAB | -63.21 | 123.79 | 7.01 | 28.33 | — | -0.12 |
| ZYME | -13.63 | 25.01 | 54.57 | -15.12 | — | -4.04 |
| NVAX | -6.72 | -8.82 | 4.06 | -8.81 | — | -0.60 |
| SNDX | -7.11 | 105.59 | 6.30 | -13.61 | — | -0.88 |